GYANT CEO and Chief Medical Officer to Join Top Healthcare Leaders in Discussion around AI, Chatbots and Voice-Activated Devices

Pascal Zuta and Alan Young to explore opportunities and challenges with healthcare technology innovation at Health 2.0 2019

SAN FRANCISCO–(BUSINESS WIRE)–GYANT, the patient connection and relationship management company, today announced that the company’s Co-Founder and CEO, Pascal Zuta and Chief Medical Officer, Alan Young, will speak on a panel titled, “Workforce Extenders: The Next Generation of Decision Support,” on Tuesday, September 17th at Health 2.0 2019.

Thirty percent of healthcare costs are spent on administrative activities (Business Insider Intelligence), and roughly $32 billion is wasted each year with unnecessary Emergency Department visits (United Healthcare). AI-powered technology has the potential to not only eliminate unnecessary spending by more accurately directing care, but, with the right level of human intervention, enhance the systematic and complex processes unique to the healthcare system, ultimately improving the patient experience.

The session, which will take place at 11:10 AM in Mission City B4 at the Santa Clara Convention Center, will delve into how organizations are using innovative technologies such as AI, chatbots and voice-activated devices to streamline clinical workflows and better diagnose patients. Panelists will also explore challenges, opportunities and concerns with widespread industry adoption of AI-driven technology.

“The healthcare industry is at a tipping point. Consumers are demanding personalized, streamlined experiences and organizations that are not able to provide them risk losing valuable revenue,” said Zuta. “At GYANT we are committed to creating enjoyable healthcare experiences and we are excited to connect with our peers to discuss how a delicate balance of AI and human-driven interactions are critical for creating more meaningful patient-doctor engagements and better outcomes across the continuum.”

For more information about how GYANT drives more meaningful patient-doctor engagements while improving care utilization and pathways, please visit here.

About GYANT

GYANT, the patient connection and relationship management company, drives more meaningful patient-doctor engagements while improving care utilization and pathways. Leveraging its customizable, artificial intelligence-enabled platform, which integrates into any EHR system, GYANT creates easy to navigate and enjoyable experiences for patients that equate to cost and time savings, and improved patient conversion rates for health systems. GYANT’s unique combination of deep intelligence, physician oversight and a human-driven, empathetic approach allows health systems to solve for traditional complex care issues, ensuring that patients receive the right care – anytime and anywhere, increasing engagement, trust and loyalty along their entire healthcare journey.

The company was founded in 2016 by two serial entrepreneurs who knew there had to be a better, much simpler approach to healthcare. GYANT is trusted by some of the world’s most well-respected healthcare organizations for its proven ability to enhance the doctor-patient relationship by maximizing doctors’ time, enabling them to focus on the patient while providing unmatched clinical care. For more information, visit: www.gyant.com.

Contacts

Erin Smith, 617-502-4371

gyant@pancomm.com

Staff

Recent Posts

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

15 minutes ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

15 minutes ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

1 hour ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

Hallmark Adds Senior Executives to Enhance Customer Success and Strategic Partnerships

New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…

3 hours ago